Overall, the results suggest that pharmacological c-Abl inhibition has a beneficial effect on the phenotype of the SOD1 G93A ALS mouse model, in delaying disease onset and improving neuronal survival. Here, ABL1 is linked to amyotrophic lateral sclerosis.